Stay updated on AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial
Sign up to get notified when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.

Latest updates to the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page
- Check7 days agoChange DetectedAdded a funding note indicating a 2018 U.S. NIH grant/contract. Added a forthcoming publication citation for Pfister R et al., 'ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis' in Cardiol Ther, 2026 Aug 20.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAn additional publication citation with a long author list and the plain-language summary of acoramidis was added to the Publications section. A new revision tag (Revision: v3.6.5) was introduced and the previous tag (Revision: v3.6.4) removed, reflecting an update to the study's documentation.SummaryDifference0.1%

- Check28 days agoChange DetectedAdded a new publication citation to the Publications section for a 2026 JAMA Cardiology study that analyzes acoramidis (AG10) effects on heart failure-related health status in ATTR-CM. This external analysis expands the evidentiary context of the trial’s investigational drug.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision label on the page was updated from v3.6.3 to v3.6.4, indicating a new version of the page or its underlying template. This appears to be an administrative update with no impact on study details, eligibility criteria, or user-facing information.SummaryDifference0.0%

- Check56 days agoChange DetectedA new publication citation by Testani JM et al. is added to Publications, describing the effects of acoramidis on kidney function in transthyretin amyloid cardiomyopathy (Circ Heart Fail. 2026). This entry updates the study record with recent related literature.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page's revision indicator was updated from v3.6.0 to v3.6.3, reflecting a new version of the page template or documentation, while the study details remain unchanged.SummaryDifference0.0%

Stay in the know with updates to AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.